Xellia Pharmaceuticals ApS
Exhibitor at CPhI Worldwide 2017 stand 91C80, Finished Dosage Formulations
Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
Xellia is wholly owned by Novo Holdings A/S.
Production Sites: Five state-of-the-art manufacturing facilities located in; Denmark, Hungary, China and in the U.S.
Expertise: Xellia has over 100 years’ experience in the development, manufacture and supply of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Xellia is the leading supplier of the important anti-infectives Vancomycin and Colistimethate Sodium (CMS).
Specs about this supplier
|Sales markets||Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America|
|Affiliated categories:||Antibiotics |Generic APIs |Finished Dosage Forms More|
Products featured at CPhI Worldwide 2017
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation